Important Announcements

Nondiscrimination Statement Update

Boston Medical Center Health System complies with applicable Federal civil rights laws and does not discriminate on the basis of age, race, color, national origin (including limited English proficiency and primary language), religion, culture, physical or mental disabilities, socioeconomic status, sex, sexual orientation and gender identity and/or expression. BMCHS provides free aids and services to people with disabilities and free language services to people whose primary language is not English.

To see our full nondiscrimination statement, click here.

Campus Construction Update

Starting September 14, we’re closing the Menino building lobby entrance. This, along with the ongoing Yawkey building entrance closure, will help us bring you an even better campus experience that matches the exceptional care you've come to expect. Please enter the Menino and Yawkey buildings through the Moakley building, and make sure to leave extra time to get to your appointment. Thank you for your patience. 

Click here to learn more about our campus redesign. 

Announcing the 2023 Integrated Pilot Grant awardees

Stethoscope and Electrocardiogram

We are pleased to announce that 42 investigators, from across BMC and the BU Medical & Charles River campuses, applied to the Integrated Pilot Award Program, sponsored by the BU Clinical and Translational Science Institute. From our pool of applications, 14 outstanding pilot projects were selected for funding, totaling an allocation of $645,000. We congratulate all of the recipients and look forward to your contributions to translational research.

Naltrexone for the Treatment of Cannabis Use Disorder in Pregnancy

Co-funded by BMC and BU CTSI

Team

Kelley Saia, MD - Lead PI

Cecily Barber, MD, MPH

The primary objective of this study is to gain pilot data on the relative safety and efficacy of the use of Naltrexone (extended release; trade name: Vivitrol) (NTX) in pregnant persons with cannabis use disorder. The outcome measure of this study will be quantity of cannabis use, defined by survey and laboratory data assessing cannabis consumption. All key outcome measures are as follows: 1) participant outcomes [cannabis consumption, retention in care, preterm birth, and side effects / adverse events); 2) fetal outcomes (intrauterine growth, fetal anomalies).

Assessing and Addressing Implicit Bias within Healthcare-acquired Infections (AAIm HI)

Co-funded by BMC and DOM

Team

Shana Burrowes, PhD, MPH - Lead PI

Cassandra Pierre, MD, MPH, MSC

Angelique C. Harris, PhD, MA

Implicit bias training is becoming more prevalent across healthcare but has not been used to specifically improve a targeted healthcare outcome. This proposal aims to reduce implicit bias in healthcare and innovate the use of implicit bias training to improve specific patient outcomes (i.e., HAIs) impacted by racial bias.